PRESS RELEASE published on 01/22/2025 at 07:00, 1 year 3 months ago Preliminary results 2024: SBO with strong cash generation and solid results despite challenging market conditions Schoeller-Bleckmann Oilfield Equipment AG reports strong cash generation and solid results for 2024 despite challenging market conditions. Preliminary results show resilient performance Financial Performance Market Conditions Preliminary Results Cash Generation Schoeller-Bleckmann Oilfield Equipment AG
PRESS RELEASE published on 01/22/2025 at 07:00, 1 year 3 months ago Statement on media report Cicor Group responds to media report about potential acquisition of Éolane France businesses. Discussions ongoing with relevant authorities. No further comments at this time Acquisition Cicor Group Discussions Éolane France Media Report
PRESS RELEASE published on 01/22/2025 at 07:00, 1 year 3 months ago BIOSYNEX SA: LANCEMENT D’UNE AUGMENTATION DE CAPITAL AVEC MAINTIEN DU DROIT PREFERENTIEL DE SOUSCRIPTION L'entreprise BIOSYNEX SA lance une augmentation de capital avec maintien du droit préférentiel de souscription pour un montant cible de 7,99 millions d'euros. Détachement du DPS le 24 janvier 2025 Augmentation De Capital Droit Préférentiel De Souscription DPS BIOSYNEX SA Montant Cible
PRESS RELEASE published on 01/22/2025 at 07:00, 1 year 3 months ago Communiqué de presse : Approbation du Sarclisa dans l’UE – premier anti-CD38 en association avec le schéma VRd de référence pour le traitement du myélome multiple nouvellement diagnostiqué de l’adulte non éligible à une greffe Approbation du Sarclisa dans l'UE en association avec le schéma VRd pour le traitement du myélome multiple nouvellement diagnostiqué de l'adulte non éligible à une greffe. Troisième indication approuvée en UE Traitement Myélome Multiple Sarclisa VRd UE
PRESS RELEASE published on 01/22/2025 at 07:00, 1 year 3 months ago Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma EU approves Sarclisa as first anti-CD38 therapy in combination with VRd for transplant-ineligible NDMM based on positive IMROZ study results. Third indication for Sarclisa in the EU Multiple Myeloma Sarclisa EU Approval VRd Anti-CD38 Therapy
PRESS RELEASE published on 01/22/2025 at 06:25, 1 year 3 months ago Xebra Brands Announces Non-Brokered Private Placement and Concurrent Debt Settlement Xebra Brands Ltd. announces non-brokered private placement and debt settlement to raise funds for operations and growth opportunities. Expected closing on January 30, 2025 Private Placement Debt Settlement Fundraising Xebra Brands Ltd. CBD
PRESS RELEASE published on 01/22/2025 at 00:05, 1 year 3 months ago Heading on Your First Cruise? 5 Tips on How Not to Ruin Your Vacation Guide for first-time cruisers: tips for packing essentials, maximizing onboard experience, staying connected, saving money on transportation, and staying safe. Expert advice by Meruyert Sarsebayeva Safety Cruise First-time Packing Onboard Experience
PRESS RELEASE published on 01/22/2025 at 00:00, 1 year 3 months ago MedMira Receives Investigational Testing Authorizations for Multiplo(R) TP/HIV Self-Test and Non-Professional Use Applications MedMira receives Investigational Testing Authorizations from Health Canada for clinical trials on new applications of its Multiplo® TP/HIV rapid test, expanding testing options in Canada amid rising syphilis and HIV cases Clinical Trials MedMira Investigational Testing Authorizations Multiplo TP/HIV Rapid Test Syphilis And HIV Cases
PRESS RELEASE published on 01/21/2025 at 23:00, 1 year 3 months ago abrdn Emerging Markets Equity Income Fund, Inc. (AEF) Announces Commencement of a Cash Tender Offer abrdn Emerging Markets Equity Income Fund, Inc. announces cash tender offer to purchase up to 20% of outstanding shares at 98% of NAV. Shareholders provided with important information on SEC filings Investors Closed-end Funds Tender Offer Abrdn SEC Filings
PRESS RELEASE published on 01/21/2025 at 21:00, 1 year 3 months ago Levée de fonds de 0,25 MEUR Néovacs annonce une levée de fonds de 0,25 M€ par l'émission d'OCEANE-BSA pour financer la recherche sur les allergies et les investissements en BioTech et MedTech Biotech MedTech Levée De Fonds Néovacs OCEANE-BSA
Published on 04/24/2026 at 22:05, 1 hour 8 minutes ago Critical Elements Mourns the Loss of Director Marc Simpson
Published on 04/24/2026 at 22:05, 1 hour 8 minutes ago Critical Elements Pleure la perte de son administrateur Marc Simpson
Published on 04/24/2026 at 22:00, 1 hour 13 minutes ago Kidoz Inc. to Present 2025 Results and Highlight Platform Expansion and Business Momentum
Published on 04/24/2026 at 15:00, 8 hours 13 minutes ago Norsemont Reports Significant Copper, Lead & Zinc Values in Three Choquelimpie Drill Holes
Published on 04/24/2026 at 15:00, 8 hours 13 minutes ago First Canadian Graphite Appoints Scott Kelly As Chief Financial Officer
Published on 04/24/2026 at 22:43, 29 minutes ago EQS-Adhoc: Marley Spoon Group SE: Closing of the financing transaction in connection with the financial restructuring of its German subsidiary Marley Spoon SE with increased financing amou
Published on 04/24/2026 at 22:05, 1 hour 8 minutes ago Berlin Heals Presents Positive Late Breaking Results from the CMIC-III First-In-Human Less Invasive Study
Published on 04/24/2026 at 18:30, 4 hours 43 minutes ago EUROPLASMA: Tirage de 400 obligations convertibles en actions nouvelles pour un montant nominal de 2M€
Published on 04/24/2026 at 18:12, 5 hours ago EQS-Adhoc: clearvise AG reviews dividend proposal in line with its dividend strategy and postpones Annual General Meeting
Published on 04/24/2026 at 18:07, 5 hours 5 minutes ago DEAG sets new records for revenue and earnings in financial year 2025 – excellently positioned for long-term growth
Published on 04/24/2026 at 18:48, 4 hours 24 minutes ago Laboratoires Euromedis - Communiqué résultat 2025
Published on 04/24/2026 at 18:00, 5 hours 13 minutes ago SMTPC - Communiqué sur la mise à disposition du Rapport annuel 2025
Published on 04/24/2026 at 17:45, 5 hours 28 minutes ago Imerys-04-2026-information-share-capital-and-voting-rights-as-of-31-March-2026